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IN'l'RODUCTION 
Inhalation therapy may be described as a method of 
introducin9 ffi(~dic.:i.nal compounds in t:he form of finely divided 
solid pa.x·t:icle.s or· fi.ne liquid mists, into the respiratory 
system in order to produCE! intended local and/or syste:roic 
t:herapcn1t.ic t::ffects Cr) ~ 
Y.-l<.:~dicinals U13EK1 in t .. he treat.:ment of nausea have trad:i.~ 
tionally been administered via oral, parenteral or rectal 
routes. Each of these methods has certain disadvantages: 
1) ox-al medicat:.ion re!quires at: least one·~half holtt• 
to produce a:n. !';f;Eectl' i::'md '!::hen. i.t ma.y not be tolerated by th(;) 
pat:ien·t, 
2) pa::r.:·cmt0xa.ls a.r.e rapidu but t.hey require sterilE' 
conditions for preparation and do not lend themselves to sel:E·-
admJ.nistra·tion, 
J) supposi t<n .. "'it:~s are both relatively slow acting and 
inconvenient to use. 
For these reasons and. ·the inherent advantages of aerosol 
therapy t an anU.na:usea:o:t ef:fecti ve via oral inhalation v,rould 
bo bene:Eid.al .. 
'11l'te follo-vd:nq adva.nta;p:-:s of mf~dicinals administered 
vi<:'t. oral J.n.hala.tion have been surr1.roarized: 
1) medicinals fo:cmerly given as an injection can be 
gi.vcm by i.nha1a.t:ion, thereby making it more convenie:n.t. for 
S(~lf~~med.ica:t:Lon by the patient .ra th.er than by medica.l.ly 
2 
t.ra:f.ned. iJersormel, 
2) response to drugs when administered by inhalation 
is prompt, faster in onset of activity as compared to drugs 
· givf.m orally, and \,ri th most dt"ugs approaches intravf.mous 
therapy in rapid! ty of act:ion6 
3) s.ince · the dru<Js are absorb·~d directly into the 
blood stream via t:he lungs§ there is no decomposition or loss 
of drug in thE..-'l gast:rointestlnal tract, as when the drug is 
adrn.:tnlsterr.;d orally.~~,__ _______ _ 
4) the dangers of giving medicinals by injection 
(t..xauma, embolism~ sterile abscesses, etc.,) are avoided since 
inhalation therapy \\Till often rf~place an injectable product, 
5) the use of medicinals by :inhalation does away -vlit.h 
parenteral admin:'t.stx·a:tion ( 2) .. 
1'tceo;t•d.in(Jly ,, it \Wttld seem appropriate that studies be 
conduct:ed on the development of an oral inhalation dosage 
form antinauseant~ The pl~esent project will consist of 
developing and testing a series of aerosol formulations to 
determine their feasibil.i:cy i.n antinawJeant therapy~ 
press\.u·ej valve releas(:.1q spr<:~.y pattern, particle size, and 
aging stu.diElS will be pel~formed. The present work will also-
include an j.n yj._y,2. evaluation of promising formulations .. 
SURVEY. OF THE LITERA'l'URE 
The aerosol dosage form for the application of 
therapeutically active ingredients represents one of the 
major advances which has occurred in pharmaceutical tech-
nology during the past decade., Since the aerosol do.sage 
l)-------.f':,:;J.~In-i-s-co-nve-x:;.-i-e-n-t-ter-u.-se--a-nS.--a-1-l-e!JlS--£a~-a----c;~eater---de~Jr-ee 
of flexibility :ln administ.ering medicinal ag-ents than othE~i:' 
dosage forms, its use has become widespr(~ad and has ext:Em.ded 
to almost all types of pharmaceutical and medicinal prepara·-
tions (3) .. 
The ;n.amc !Jaerosol 11 in :l-t:;; scienti:f:ic sense denot;~~s a 
colloj.da1 sygtElm consistj.ng of f:i..nely divided liquid or s(:-lid 
particles disper~:;ed in and surrounded by a gas; ·typical 
examples are smoke 51nd 'fog.. The pa.r.··t:.i.cle s~zes nx·e usually 
less than ten microns.. Now, hot'leve.:r. 1 the name '
1aeroso.l" .ir;> 
accepted for a cont:~dner filled with a liquef.ied propellant 
plus functional product fitted ,...;1 th a. px·ess-buttt.:m Vt:11 ve v 
and pressurized packs are commonly known as ;:u~rosols {4} .. 
'l'he:ce are 1:hree broad groups of modern p.ressur:i.z~d 
. packages.. 'I'hE;sa include~ 
1) space-~ spraysg 1 .... rhich ru.·e finely divided sprays, 
exlu.b:iting pa.rticle size ranging up to 50 microns in dlameter, 
2) suxface coating-s, 'tvhich are also sp:cays, but: are 
coarser in size, 11\'letter," and designed for con·tinuous film 
fox.~mation ox1 a su:t'fi::lCE;~, 
3) aerated foams, produced by the expansion of certain 
pro:pellant:.s uthrough 11 an emulsion, giving r .:l.sE~ to numerous 
mnall bubbles~ Examples includ.e shaving- creams and v1hipped 
vlh.ile tb.e development. o:f the pX'l~.ssurized package as it 
is known t:oday is of 1:·ather rc~cent: origin 3 thE:~ at;omi?.a.tion of 
particles for use in ac~rosol tht:~rapy is not new... Eiucb. dHvi.ces 
-----
as burning sulfur candles t:o disinfect air 0 spraying opr.:::x·at.ing 
rooms with. germicidal materials, and inhalaJcion o:f the srnoke 
of ast.hma powder are early examples of aerosol therapy ( 3) .. 
Sb=:;am, or medicab:~~d steam inhalation~' and the inhaJ.2:tion of 
perh.a.p.s still u.sr.~ful £-.!X~tmples of ae:r.o:;:ol UH,~rapy of t:he lungs 
{6) .. 
Slv:::ph.erd ( 7} ::>ta·ted ·i:hut. as early <'.iS 1899, Helbing and 
'i 
Pertsch :31:H:;;gested means of propelling· confined suhstanc<~s 
thrlJugt1 u.:se of liquids such as meth.yl and ethyl chloridr-3.. In 
1901~ 1902, and 1939 Gebauer was issued patents describing the 
use of presDurized packages for dispensing medicinal agents 
such an t . .:-rn.n:Lc acid and et.hyl chlor :ide< In fnct t:.he use of 
ethyl chJ.or.ide as a local anesthet.:Lc J.s considered by many t.o 
be tt~.r.:~ fo:ct:n;irmer of the p1~esent: day aerosol ( 7J.. Seyeral 
ant.iseptic ~.-:;oJ.u~~-icms an.d perfume aerosols -.;·mre developed usinsr 
carbon dioxide as tho propellant. 
Other chemical agent:s Hfn-e invest.iqat.ed duri.nq the 
.l930~s as p6ssible propellants, including fluorinated chloro-
hydrocarbons v1hich \·Jere o:riqinal.ly developed z.1.s :refrigerants .. 
On.t~ of these materials, dichJ.orodifluo:comethane, was used by 
Goodhue and Sullivan as the propellant in their aerosol Ln.sec-
ticide which they d.eveloped for the U~ s .. Department of 
Agriculture.. These insecticides were used by ·the Armed Forces 
during World War II to combat the various insects w·hich caused 
disease among overseas troops. The aerosol '\vas packaged in a 
high-pressure cylinder of heavy steel construction and had a 
vapo.r pressure of 70 pounds per square inch gua!Je {psig) a at 
70° F. Interstate Commerce Comrn.i_s_siQn_r_e_gula:cion~Lnecessi -------
tated a heavy, bulky steel container for shipment of these 
products (3). The first let17 pressure formulation containing 
dichlorodifluo.romethane was not developed until mid 1943 (8)., 
Following World War II newer propellants, valvesB an.d 
c.on:taine.rs vJere dt:.vcloped so that a spray possessinq the 
pro~);r· particle .size could be produc,J.d using a pressure of 
35~-40 psig.. An c.:o..mendnw.mt to the .regulat:ions of the Xnte:t·st::ate 
Commerce Commission in 1947 made possible the use of a t:hln= 
walled container by permitting a pressure of 40 psig at 70° F 
in essentially a 11 beer-type 11 container. Other contaim,;r 
developments included the use of stainless steel and aluminum 
as well as glass and plastic .. 
Another area of development essential to the success 
of the aerosol package concerned the va.lwl.. Various va.lvHs 
were develop(;';!d in o::.~der to dispense 'che product in. the form 
of a fine str·eam, a fine mist, a coarse spray, or solicl st,·eeam .. 
a ·- 'l'he t.errn "psiq11 represents the uncorreci:ed p:.r:esstu.:e and 
is t.o be distingui.shed :fx:om "psi<:," (pounds :rx"--:J: squa.re inch 
absolute) i.:hat: is ccn.~rected t:o include atmospheric pxe.s-
sure (14.7 psig)~ 
Still a:n.otb.er developmE:mt 5.ncl uded the tneterr::d valves ~lh:Lch 
~lJ:"<~ essent:t<:\1 for mocl.i.cina.l aerosols., The.-:11~' va.l ves nuike it 
possi.bl~.~ t:o dispen:::;e quant:H:::ie::'! of? medication rang·ing from ~::iO 
United States in 194'7" A~c that time, the a(;;z.·osol insec·cicide 
was esse:n.tially the only aerosol prod.ui:!t available. Ji'rom 
194 7 to date the ae:t·osol. industry has grc:n·m f'rom. a total 
product:.ion o£ abo·ut 5~ m:U.:.U.m:~ lmi·t::~~Ll~_.t'._y5)_a:~:____and_cmly_m1H. _____ _ 
p:.t·oduct, to a p.r.·oduction o:f over 2~ billion units a yecum in 
196 8, repres.::mt:ing a multi t:ude of products ( 3) .. 
~!he growth of pharn1at;eu.tical and medicinal aerosols 
ha.s· al~~o be~~.n phenomenal." In 1964 the:t~e \-!as a total volume 
of:)ler~s t:h.an 50 mJ.llio:n 1n:1.its (9).. In 1968 \'J'elJ. over 50 
mil:].lon uni.ts wer·e produ.ced in the Uni.ted States.. '.rh.is .r:Lsing 
to(t'al included a ·\rariet;y o:f over 60 d.:Ltfe:r·ent a.et·osol productr.;., 
When it is noted that less than one million units of these 
produc·ts were produced in 1952, the newness of the develop ... 
ment and the increased i.nterest in this ro:.·ea are quickly 
realized (3). 
~~~~.iE};§. 
'!'he re'l.atively simple principle upon which the aerosol 
mechanism .is based considers that. a compressed or. l.iquefi(~d 
g'e'\S exerts a force Upon the internal surfaces Of the container 
in which 't.ll{~ gas is enclosed. 
The pr,essure of a.n aerosol system refers to the pres-
sure being exerted by the vapor within the conta:ln.l':1r., A 
lj.;quefled gaE; in. a seal·ed cont:ainer appeat-s l..rlthin the 
7 
contaj.ne.r in two phases. One is the liquefied gas itself and. 
the other is composed of the gas vapor which has volatilized 
from a part of the liquid and fills the space above the liquido 
It is the pressure of the vapor in equilibrium with the liquid 
which exerts the force against the internal walls, the liquid, 
and all accessory packaging components within the container$ 
As the aerosol valve is opened, and the containex.·' s contents 
have ac::cess t.o the atmosphere, these contents are pl~opelled 
out of the container by the higher_tP.a!l ati!lO.E;p_h~:ri._q_p:r:~~:~_sure,__-____ _ 
condition within.. The vapor pressure referred to may also be 
supplied by a noncondensable gas which has been compressed 
within the container (5)~ 
!!_!g}.l~~~.:!~_c;t __ Qas ..S~1 
Liquefied qases ha".re been '\rlid.ely u.sed aB px>op~~llan.ts 
'for many aerosol p:t:()dttct.s. 'l'hese: ccrmpounds are useful for 
this purpose sinc:e they are gases at rootn temperature and 
atmospheric pressure. However, they can easily be l:i.quefh~d 
by lo-v1ering the temperature below the boiling point or by 
increasing the pressure. 
Most .of the liquefied propellants used in aero.sol 
formulations exhibit sol vent. characteristics similar to non--
polar organic solvents. 'l'hey are very poor sol·vents for pt)lar 
compounds and are immiscible wit:h polar llquids.. ln :tnstances 
where sol'txtions of pol ax· substances are tjesirable or required· 
these propellants cam1ot be used alone. At ·times, ho\'lever, 
the use of co~solvents can solve the solubility problemH .. 
Aerosol terminology defines the 1:l'lo·~phase system as 
having one vapor and one liquid phase., Any nonv·olatile 
:mat::e.•xial d.issol ved in the li.quid phase is left suspended in 
air <3.::> a :f::.t.ne dispersion immedi.at.ely aft:er spraying as the 
liquefied propellants bodl rapidly m<Tay. Because of the poor 
solvent porne:t: of the haloca:r:bon propellants for polar com-
pounds, only nonpolar mate.d.als are directly dissolved by them. 
Efforts to increase the ,sc)l vent po\V"er of the liquefied halo-
carbon propellants have centered mainly on the use of 
co-solv<m:ts.. The a.ddf,~d solvent becomes em important: faetor 
ln such systems., It: not only_d:i:tr<::1I:_s_:i._f .. ie.!:!____and __ enb_an_ces the....__ ____ _ 
solvent action of the propellant, but also exercises a con-
siderable role in determining ·the char.act:eJ~·istics of the spray 
p:.codttcEKl and the applicability o:f ·the so.lui:ion (10).. 
One method of obtaining sprays containi.ng water soluble 
·:cr.nnpnun.ds i;:; tJ.u? l.f.;~\(:: of the ·three-~p:tv:1se syst.,.?:m.. 'i'his aerosol 
(~{.)l~\tn.i ns water o:r. <::tt1 a.qu.eous solution plus t.he liquefied pro~ 
p:i:::lJ.cm .. t Hhic.h f~)XW.s <::t separate lay<~r" either belo\'1 or ctbove 
·the aqueous layer, depending on relative liquid dens:i.ties .. 
The two imrniscible liquid layers and the vapor in the head-
space of the sealed container constitute the 11 three phases" of 
such systems... When the propellant layer is 011 the bottom of 
the container, a dip tube, or standpipe, mus·t be attached to 
the valve and its length adjusted so that it does not extend 
i:nto the liquid propellant phase. In such a system, ·the aqne~ 
ous layer is maintained as a solution until sprayed.. Actually 
the propellant phase serves to supply the pressure required to 
force the aqueous solution up the dip tube and out of the con-
tainer e It does not materially affect i:he character of the 
spray; this becomes the function of the valve components and 
9 
solvent system (10)~ 
f£.11)E.r~-~s-~.d G~~ A~ 
Compressed g-ases are used to dispense the aerosol prod·~ 
uct as a solid stream, wet spray, or foam~ Thc.:;se product:.s 
utilize an inert gas such as nitrogen, carbon dioxide 6 r)r 
nitrous oxide as the propellant. As the name indicates, the 
gas is compressed in the contain~:~r, and it is the expansion of 
th<."l' compressed gas which provides t.he force necessary to expel 
the conten·ts from the~ container ( 3) • 'l'h:ls type of system ha.s 
cet··tain inherent disadvantages: 
1) a large gas spaCE'i is requ.ired in the container. to 
xnaintain sufficient pressure to empty ~;he contents, 
2) pressure decreases as the conten·ts are discharged 
'9i vi.ng :cise to eh.::tngt.~s in the nature of the spray, 
3) the possibility of misuse causing an accidental 
discha:Cc;J'e of ga.s f.'!Ontent which produces an inoperable prod-~ 
uct {10) .. 
~,!'_§yst:~ms 
1. E. :k~.!L1'Xl2.8. 
Since it is difficult to completely ~~rnpty the contents 
of a semisolid from an aerosol container, a piston type aerosol 
system has been developed.. 'l'his uti.li~-.es a free moving pli:1stic 
piston in a coated extruded aluminum container., The concen·~ 
tt.·atE:' is pla.ced into the upper portion of the containeJ." o 'fhe 
product: itself provides the seal betHeen the pis·ton and the wall., 
The pressure from nitrogen (100 psig) or a liqw:~fied gas pushes 
against 'the other side of the piston; and ~1hen the valve is 
10 
opened,·· the product is dispe:nsed., The p:i,.ston scrapes against 
the sides of the container and dispenses most of the product 
concentra·te (11}. 
2.. Plastic B_9.g •rvP!:. 
'!"his system consists primarily of a me·tal container 
equipped 1>1ith an inner plastic bag that holds the product.. The 
pressure ·that forces the product out of the plastic bag and 
through the valve is supplied by the propellant which is l(!aded 
t-----'t~h~:r..._:o=u...._.qh the ho·ttom of t:he can_and_r_emains_o_u±:si.de_the_hag~_'J~he. ___ _ 
plastic bag" therefore, serves as a barrier that prevents the 
propellant from coming into contact with the product. These 
sys·tems have a number of advantages and should open up the 
field fo:r. many m:nv- products ( 11) .. 
Several ne>,\r systems are based on the aspirator p:r.inc:i.-
ple.. The .propellant is kept apar·t from the product until disM· 
charge.. The assembly consists of a power unit, which contains 
the prop:el.lant and a product container. The latter is at 
atmospheric pressure at all times~ t.herefore 1 its construction 
is not limited by pressure regulations. This allows consider-
able f!e1dbili ty in the design of the product con·tainer as well 
as in the materials of construction (12)., 
'l'his system was developed to separate the reacting 
ingredh:n1'ts that, are used in the production of hot foams. This 
unit is insf.:::rted into a regular aerosol container and crimped 
in place in the usual manner. The oxidizing agent: is placed in 
the inner contGl,ine:r: o A reducing agent is mixed with 1:he ernul-
sion fo:~;·:mula:tion and plac:ed into the outer container .. 
11 
When used, a measured amount of each component is 
dispensed and allovled to mix in the valve. An exothermic 
reaction resu.lts with the liberation of sufficient calories 
to heat thC:c~ foam.- 'I'his system has been used to dispense a 
hair conditioner and can be used for a variety of pharmaceu-
tical products· 'tvhere heat may be desi.r·ed or where incom..;. 
patible ingredients may be present (3)& 
One of the mos·t intriguing aspects of aerosol formula-
tion is the dual role played by most of: the currently avail-
able propellants.. These supply the necesscu.·y energy ·required 
by the self·-propelling features of ·the aerosol, and, in addi- · 
tion, become an integral component of the contents.. In many 
i:nstances t:l:1~ p:t:'Of't.~llant used may be quite satisfactory .tn 
supplying· pxessU.I::'·e, bu·t at the same t.ime introduces seriou::. 
problems 't'lhich affect therapeut:ic efficiency and product 
s·tabili t.y., It can be seen that the choice of propellant in 
a,n aerosol formulation is of critical importance. 
1.. Li_gu~.f~4__fjases 
The liquefied gas compounds have found widespread use 
as propellants sinc~:l they are extremely effective in dispel-: s-
ing the active inq;;;·ed:ierrt:s into a mist o1: foam depending on 
the form desired.. In addi't:ion th.ey are relatively :i.I'le:r:t and 
nontoxic. They haVEi the added advantage that the pressur~ 
't.qi·thin the container remains constant when these gases are 
usecl as propellants.. Of the two types of liquefied g·ases 
used, the fluorinated hydrocarbons have found greater use due 
to their norlflammabili ty than the flammable hydrocarbons .. 
Howew~r, the hydrocarbons are less e:x.pensi ve than the 
fl:uorc)carbons and are finding increased use in shavt'?. foa.m.s 
and other l1llater based aerosols .. 
·· Several of the fluorocarbons have been used as px:o-
pellants. In fact a majority of cornmerci.al aerosol produc·ts 
ntake, use of these materials as propellants 0.3) e Thesr) pro""' 
pellants are primarily derived from methane, ethane, and 
cyclobutane by replacing one o:r more of the hydr.og~ms of 
these compounds with chlorine and/or fluorine (3~-
The mos·t unique member of this family of propellants 
is octafluorocyclobutane (Propellant C-·318).. This none~ 
chlorinated cyclic compound is consideredthe most stable of 
t;he, halocarbon propellants and has been cleared for use wi·th 
edible produc!ts (.10) .. 
In o:rd\':IJ:" t-o refer easily to the fluorinated hydt•o..., 
· g:~;:~J."htms a x·elat.i v~;ly simple system of nomenclature ·N·as 
developed by the refrigeration industry., A numer:tcal desig-
nation i.s t1sed to identify each propellant (14).. The rules 
for numerical designation are as follows: 
1) all propellants are designated by three digits .. 
iihen the first digit is zero, the propellant is designated 
by t.wo digits, 
2) the first digit is one less than the number of 
carbon atoms in the compound. Where there art:~ only t:wo 
digits, zero is understood to be this figure and indica·tes 
a methane derivative, 
3) the second digit is one more than the numbe1· of 
hydrogen atoms i.n the compound, 
4) tlbte last digit represents. the number of fluorine 
atoms, 
5) the number of chlorine atoms in the compound is 
found by subtracting the sum of the fluorine and hydrogen 
atoms fx·om th•e total number of atoms which can b~ added to 
saturate ·the,· carbon chain, 
13 
6) in the case of isomers each has the same number 
and the most symmetric one is indicated by the number alone .. 
.P .. s the isomers become more and more asy-nmtetri_e_. __ the __ l_ed:.±~r-a.r----­
b, c, etc .. , :follows the number, 
7) for cyclic compounds a C is used before the num-
Several chlorinated hydrocarbons have been used as 
pro};i~~llants •'O'Y: .in ,coml::d.na:tion wiU1 o~t.her propellants in 
var:t'ous t.ype ;aerosols,. Vinyl chloride, methylene chlori.deiJ 
and .:;trichlo.r·c1ethane have been used. They are especially ur:>e~, 
ful in insecticidal sprays, certain hai:t• sprays, and room 
deodorants (3),. 
Hydrocarbon propellant gases, such as propane 8 !so-
butane, and~butane have seen limited use in nonpharmacc:mtical 
aerosols. Their chief disadvantage is their flammability when 
used alone, .but it is claimed that this hazard is minimized 
when these compounds are mixed \vith halocarbon propellants., 
The possi.bil.ity of lealcs of these flammable propellants from 
Stored contai:ners, however, has become a matter of concern .. 
The danger of containers failing or being crushed in shipment:, 
whel'l exposed .to excessive temperaturf~s, could present a 
ae).·ious e:x:pl.osion risk with gases such as butane (lS). 
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'I'he compressed gases such as nitrogen, nit.rous oxide, 
and caT:bon dioxide have been used as aerosol propellants¢ 
Depending- on the nature of the formulation and the valve 
design, the product can be dispensed as a fine mist, foa.m, 
01~ semisolid. Unlike the liquefied gases~ however, t.he com-
pressed gases possess little expansion powe:t' and will produce 
a fairly \vet spray and :foams \vhich cu~e not as stable as U.que-
dispense . food products and for nonfoods to dispense t:he product 
in its original form as a semisolid (16) .. 
1.'here are several requirements for containers which 
l?tr~.r-haps the major concern is that they should be substantial 
enough. to contai:n. pressure sqf.:.dy tJu:oughou:t the anticipated 
shelf life of the product and during various expected condi-
tions of storage and use.. Such considera:tions prompted the 
early use C)f heavy, thick walled steel cartridges as the first 
fluorocarbon gases became available (5). The first disposable 
aerosol cans appeared in 194 7.. '11hey were modeled after bee:r;· 
canse Ini tia.lly they \'lere available only with plain tin-
plate interiors, but, later, containers 't·li th single, double, 
and even triple linings were developed to help control corro-
sion (17)., 
1. Tin-Plated Steel 
~-~_,.~---:""'" 
The selection of cont:ainers is quite varied and each 
type of container presents different problemso Of all the 
met.al ,con\:ai:ners th£::: 'io.ost. popul<;1:r.:· is three piece tin~plated 
steel because o£ H:s low cos.t 11 high st.t't::!ngt:h, light .we:tght, 
and relat,i.ve ease of fabrication, It is also, hov.rever, sus·~ 
ceptible t.o corx·osion.. Plastic linings increase the :r.'esis~ 
tance of these con·t;.zdn-ers to (!Or:eosion., btlt again increase 
the p·ossibiLt.t:y of cont:aminat.ion of the formula with plrlst:i.= 
cizers .a:nd ant:iox:idan·ts... These lin;tn.gs must also be approved 
by the FDAaf<:lr use with drugs 0.8}... Host aerosol cans have 
a soldered side seam whe.t·e the body i~;t joined t:oge·l:her.. The 
----- -----·------
problems in completely cove:cing this par.ti.culal:' ar,;ia are so 
seriou~~ that even tad.ay· the . side ~•earn is cottsidered the most 
cri.tical part of the cane :fr(~tn a col:':r:nsion standpoint: U ·n .. 
avaJ.labl.e-.t 'VJ·ith and l<~ithout internal coatings., Corrosion is 
as much a eonsideJ.-ati.on for aluminum cans as it is for steel 
containers.. Xn fact., it is often more difficult to obsel.~ve 
corrosion in aluminum.,. The .one-piece aluminum can offt.~x·s mor.e 
resistance. ,to electrolytic cor·rosion than the two-p:i.ece can. 
Even though the two-piece can j,s made completely of adumintHn, 
' 
there is a di£ference between ·the hott:om and waJ.l.s of the con-· 
tainer.. Because .bot:h pieces undergo a different... typ.~ of 
fab:ricat1.on." the metal all<lys at•e a little dif:fe:rent .. 
. 3., .2.!:2.!!~}. e_E.s~l;_ 
Stainless s·tee'l containers offer vex:y good :t•esistance 
to most. produc~:s and can accommodate very high pressures .. 
a - F'ood and Drug Administration. 
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Howevere these units are very costly, ax·e·available only in 
small sizes, and are designed to accept 20 mm. bottle Vc.tl.ves 
which further increase the cost.. T1:..ese units t~su.ally serve 
very well when small dosages are to be dlspensed at high pres-
sures$ and where cost i.s not a primary.consideration (18)., 
4.. Glass 
~---
Glass containers offer very good protection for phar-
maceutlcal aerosol formulations since they do not corrode and 
do not af·fect the drug (except possibly by~gso!'ptivity) o _____ _ 
.. There have been a few cases where the pH of the product had 
changed appreciably due to the alkalinity of the glass, but 
·the·problem can usually be solved by the addition of suitable 
buffering agents or if this is not practical, by requesttng 
.. 15 psi.g for tmcocx-t:ed glass limits j_ t.s: use; however, polyvinyl 
chloride coated glass bottles can hold pressures up to 25 psig 
and newer modifications will support pressures up to 40 psig 
(18} .. 
s .. E~.lli 
A great dea.l of interest has been focused on the 
development of a suitaple plastic container., If and when this 
becornes x·ead,ily available 1 :i.t 'i"lill be necessary to determine 
the dr.?.<J:t'€H3 of permeai:ion of the propellant <:md co-sol vent 
through ·the contain,~r walls" and t.he resu.1 tant effect on the 
conci."':ntx'at:i.on of the ac-tive ingl:edient:s over extended storage 
p<-~l:fods. Permea.t:i.on of moisture :from i.:he atmt.)Sphere into the 
pl..;.H:>·tic cont.ainer could affect wat:er sensitive formulations .. 
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Here, as in plastic coatings for metal containers, the 
extraction o:f plasticizex·s, antioxidants, and mold lubricants 
must be considered. Chemical compa"l::i.bili ty between the plas-
tic pol.y.ners and the formula must also be resolve~d (18) .. 
One .o£ the most critical components of the aerosol 
package is the valve. It serves to seal the containe:r:· h(~.I'A· 
metically and .to regulate the passage of p:t:oduct from the 
of the product, complementing the des:i.gn of the formulation., 
The valve"' a.ll.:mg with the actuating device, may be selected 
to produ.ce a f.fine o:c coarse droplet distribution, a fully 
expandf.:ld foam, a slow or rapid rate of product release, a 't'lide 
:c;;x n;:n:·.r,J.w spsc:ay pa:ti:ern, or n continuous or precisely measured 
The conventional aerosol valve is composed of several 
basic components assembled together. Regardless of the manu-
facture:r $ in most instances, these parts are present- in every 
valve me.chanis·m. 
'The actuator, which is often referred to as the but·ton 
or spo~1t, provides a rapid and convenient means for releasing 
the contents tfrom a pressurized container., r.rhi.s component is 
fitted o:nto the stern of the valve or is inserted into the valve 
body and .s.erves as the final exit for product leaving the con-
ta:i.ne1~ as \1/e.ll as a means of easily depressing the valve stem. 
to start the process (S).. The actuator provides the additional 
functional use in allowing the product to be dispensed in the 
I 
. I 
desired form; that is a fine mist, wet spray, foam or sol.id 
st-t•eam. Mechanical breakup actuators are used in three""·phase 
or compressed gas aerosols. In addition, special actua·tors 
are available for use with pharmaceutical and medicinal aero-
sols which allow for the dispensing of products into the mouth, 
nose, throat, vagina, and eye (3). 
The valve stem is the component actuated ·to bring 
product forth from the contai.ner.. The stem holes are posi,-~ 
tioned so that when the stem is depressad_Ol."-tilt.ed,_.they-a.re----
expo~E;ed below the stem seal into the product contained in the 
valve body and will permit its passage to the actuator .. 
The diaphragm or stem seal, ~<Thich is made of r1.1bber, 
most often Bun a N or Neoprene, functions to seal the pror1uct 
:from th.e ste;:n o.ri.:fiC\';l., The d:bnensi.ori.:ll tolerances of this 
~ompo:nent are carefully controlled to assure that product will 
no·t pass around t:h.~ stem when the aerosol is not in use .. 
The valve cup or ferrule is the external housing for 
the valve parts and is the component which is affixed to the 
container to hold the entire valve in place. The cup refers 
generally to the one inch metal valve exterior \'Jhile the \'\ford 
ferrule is used to describe the same functional part for bottle 
valves., 
The valve spring serves to return the valve stem to 
its rest position after actuation.. l-1ost valve sterns c9ntain 
a spring, constructed usually of thin guage stalnless steel 
wire, which it~ located at or on the base of the stem and j.s · 
contained by the internal valve housing (5).. •.rhe material 
used. to construct the spring is quite important. The iron 
that ca.n be extracted from certain springs has been known to 
cause problems in some formulations.. An example of this is 
epinephrine, whose biological potency 'VIill decrease w:i.th as 
little as 50 ppm of iron (19). 
The valve housing or body serves to contain the stem 
and spring and to hold the top of the dip tube at its base, 
if one is used. The top portion of the housing is held in 
place against the diaphragm, tightly sealed to prevent the 
flow of vapor or product other than through its bottom orifice,~ 
The dip tube or eduction tube, when used, conducts the 
product from the bottom of the container to the housing tail 
orifice.. When not used, the container is held in the inverted 
position to release product (5) .. 
The.dip .tube comes into intimate contact with both 
product and propellant and therefore should be resista.n:t to 
both physical and.chemical attack. Nylon and specially 
developed polyethylene o1· polypropylene compounds are the 
materials most commonly used .. 
The tube should ex·t.:end almost to the bottom of the con-
tainer.. If the tube is too short, all of the product will not 
be dispensed, while a tube touching the bottom of the container 
will tend to block the passage of liquid. J:n this co11nect:ion, 
most materials used for dip tubes tend to elongate l'lhen 
irnmersed in certain solvents and propellants for long periods 
of time. This elongation should be anticipated when determin-
ing the length of the dip tube (3)., Dip tubes are assembled 
onto the· vaJ.ve with usually a length t.olerance of plus or minus 
a sixt.eenth of an inch. They are usually cut flat at the 
bottom~ how·ever ~ the serrated bottom is mucP, preferred to 
eliminate ·completely the possibility of sealing off on the 
base of the container (5)~ 
2. .Met~~Valy.f§!~ 
Since their introduction in 1956, aerosol mete~'ing 
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val v·es have found widespread acceptance in· the pharmaceutical 
area, particularly for inhalation aerosols. .Aerosol metering 
valves are designed t.o deliver a fixed quantity of material 
1!--____ u_pon each ac·tuation of the valve. The basi_e_principle invol.,._v~e~.s~--­
a metering chamber and a dual valving mechanism. When the 
valve is in the closed position, a seal is crea:ted between the 
material in the metering chamber and the atmosphere.. In this 
position the metering chamber is allowed to fill since it is 
~tn contact w·i th the contents of the package.. I.>ep.ression of 
the aet:uato:r opens the metering cham!:;:~er to t.he atmosphere 
through t.:he channels in the stem and simultaneously creates a 
seal beti'Ieen the lower portion of the metering chau'lber and the 
contents of the package (20). The volume of the chamber in 
which the isolated portion is held determines i;he quantity of 
spray per actuation. Hm>~ever, trade practice has been to take 
no account of the specific gravity of the product-propellant 
:mixture and to list valves with different capacities as being 
able to deliver a certain number of milligrams per actuation, 
e .. go, 50 ·mg .. , 100 mg., etc .. 
Aside from delivering predetermined doses and thus 
minimizing overdosage of active compounds, metering valves 
offer another safety feature from the standpoint of aerosol 
packages for medical uses: they pt·event the discharge of 
la,rge volumes of comparatively high pressw:e gas into body 




The filling of aerosol containers can be undertaken by 
two distinct methods. In cold filling, the product is placed 
in the container and cooled. The propellant, also at a low 
temperature, is then added and the container sealed. In pres-
sure filling; the product is placed in the container at normal 
temperature and sealed. The propellant is ·then introduced 
under pressure th:rough the valve. The danger of air being 
entrapped in the container can be avoided by evacuating or by 
purging the container by the addition of a small amount of 
propellant or nit:rogen$ Aqueous based systems must be pret.~­
sure filled as ·the con·tents may solid.ify on cooling (4). 
t},EElicatJons. 
Aerosol technology has been applied to the formulation 
of products containing therapeutically active ingredientso 
Since there are various formulation factors to consider in 
different systems, some concise definitions 'tvould appear to 
be in order. The definitions of Sciarra (3) seem to be the 
most useful. 
A pharmaceutical aerosol may be defined as an a(:'ll."Osol 
product containing therapeutically active ingredien·ts d:i.s-
solved0 suspended, or emulsified in a propellant or a mixture 
of solvent and propellant and intended for topical administra-
tion or for' administration into one of the body cavities such 
as the ear, r.t~ctum, and vagina. 
J:.iedic:l.nal aerosolst' or inhc:tlation aerosols as they may 
be called11 may be defined as those aerosol products contain-
lug the.r.apeutically active ingredients dissolved or stt'spended 
in a propellant or a mixture of a solvent and a propellant and 
intended for administration as fine, solid particles~' or liquid 
mil::>ts via the respiratory system or the nasal passages. ~1hey 
are intended for local action in i:he nasal areas, throa.Jc 5 and 
lungs, as well as for prompt systemic effect when absorbed 
-------
f.t·om the l..ungs into the bloodstream (inhalation therapy). 
The particle s.ize must be considerably belmv 50 microns. and 
. in most instances should be belmv ten microns and preferably 
between 0 .. 5 and 10 microns for maximum ·therapeutic response 
A.;:~:cosol ckn:matological or topical pr<'.;!parations ·we:c·e 
probably the first aerosol pharmaceuticals to receive close 
attention by marketers and to receive widespread acceptance 
by consumers.. Some of the advantages of dermatologicals, many 
of these also apply to all pharmaceutical aerosols, tha·t ha·ve 
caum1d the rapid acceptance by marketers and consumers are: 
1) convenient, fast, and efficien.·t application., 
2) no waste or messiness associated with applicator 
ox: cotton swab, 
3) reduced danger of contamination of the product, 
4) the elimination of air, oxygen or light in thE~ 
product reducing unwanted reactions wi thi.n the product or loss 
of active ing.redient.s, 
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5) prevention of drying out of product, 
6) reduction of irritation by mechanical application, 
7) application in. a thin layer, resulting in faster 
absorption (9). 
~dic~~~~ros_2}.s,_itt!?- Oral Inhal~~.Y.. 
Inhalation aerosols are probably one of th<.-'! greatest 
areas of opportunity for future growth in the pharmaceutical 
industry. There are several advani~ages~ previously rn.ent:ioned 
:tn t:he int:roauc-cion, to be consiaerea- in the u~u~ of oral 
inhalation aerosols for the administration of drugs.. In addi·u 
tion ·to· the aforementioned advantages of H: has been stated 
that aerosols offer reproducibility of amounts delivered that 
is,superior to oral liquid preparations dispensed by teaspoon 
o:r.\ d.ropp~::)l:r and that compare :favorably with \ve:lght ve~.r:i.at:ions 
flEix·m:i tt:>E!d for hu~Cd g(-)lat::ln capsules {23)., 
In. li.gh'l:: o"': these fact:s 1 it 'WQ'Uld be well to discuss 
the respiratory system before discussing aerosol ·therapy in 
detail. 
The respiratory system or tract consists of the nasal 
passages and the mouth opening into the pharynx, the larynx, 
the trachea, the bronchi 11 and the lungs. 
Ail"' enters the nose or mouth, passes :into the pharynx 
and thence into the larynx. The J.axynx and pharynx at'e sepa-
rated fX'Om one 2n10t.her by the epiglottis, which permits the 
passage of air or. materials suspended in air, but prevents 
the passage of liquids or solids into the larym·: during the 
swallm.,ring process. From the larynx, air enters the trachea0 
which divides to form \:he upper bronchi.. Smaller air 
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passageways, called terminal. bronchioles, a.rlse.from the 
bronchi., 'I'hese terminal bronchioles subdivide into :t.•espira.;., 
~ory bronchioles which give rise to the alveolar ducts (f:i.ve 
Qr six per bronchiole). After branching a variable number of 
times, each alveolar duct terminates in several alveolar sacs 
(three to six), the walls of which contain pouch-like struc-
tures termed pulmonary alveoli.. From the area of the respira-
to:r;-y bronchioles to the pulmonary alevoli, true respiratory 
}-----:ftJnc"tion-occtu:s-,-tha-t-i-s-,--exchange-of-gases--ta~es-pl-a.sc:-.. 
From the oral and nasal cavities to the te:c·minal 
bronchioles, these structures are fo:r: the most part lined 
w·ith mucosal tissue well supplied with arteries and veins. 
Thus, the surface they present to materials to be absorbed 
is similar to the lining of the stomach or intestine., How~·-
ever, t:here are also cilia8 or hai:r.~1:1J~e projections present: 
which beat. rhythm:l.cally and tend to propel the sheet of mucous 
which envelopes them in the direction of the mouth. This is 
the mechanism whereby the body entraps and expels fo:t·eig'n 
particles entering the respiratory passage\,n-tys v,d.th atmos-
pheric air. Not all suspended materials are eliminated in 
this way, the limiting factor being the size a.nd mass of the 
particle, and the diameter of the air passageways.. The latter 
is less important than the forme:t' 't<lhen it is considered that 
the mechanism for removing particles from the air is so effi-
cient ·that most particles larger than five microns in. diameter 
are prevented from entering the lungs by this means.. On the 
other hand, the smallest respiratory unit, the alveolar duct, 
has a diame·ter of about 200 microns. Ther'E~ is, of course, a 
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minimum to t.liM::!l size of a particle that will be retained within 
the alveolar sac. 'I'hus, those pa.:c'ticles that tend to rema.in 
suspended wit:hin the alveolar air would be expelled during 
·expiration, :those particles usually smaller than o .. 5 microns .. 
Particles be'bween these limits ( 0$5 to s. 0 microns} l-Tould ·tend 
to fall against the alveolar walls and mix with the alveolar 
fluido 
A factor which contributes greatly to the respiratory 
function of the lung is the thickness of its walls. F:r.o1tt t:he 
respiratory bronchiole to the alveolar sac, these walls con-
sist. of thin connective tissue in close contact ·t-d·th under-
lying blood ·'V':essels. In fact, the walls of the pulmonary 
alveoli consist of a single layer of epithelial celJ.s with a 
single capi.I.lary betw~:::en adjacent alveoll, so that, in most 
inst:ances, nta.:t.~rial i.n the alveolru.~ cavi i:y is separated £rom 
circula·t:ing b.lood by only tlv"O membranes, the alveolar and the 
cap:i.llary wal..ls.. The area of the exchange surface of the lung 
must also bE!! consideredo This is estimated "l::o be about 55 
square mete:t~£; or about 25 times the surface area of the skin. 
If it is kept in mind that this is also the area of the avail-
able adjacen.:t blood supply, the rapidity of absorption in this 
area will be ·more readily understood (24). 
One of the most important considerations in the useful~ 
ness of a dr·ug substance is \-lhether or not the material is 
soluble in bc,dy fluids and, therefore, capable of being 
absorbed.. 'J:<htls, a drug to be given by inhalation therapy must 
be soluble in nat.u.ral secretions. Very slo\vly soltrl:.>le and 
absorbed suhs·tances would probably also be proscribed, These 
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materials are likely to act as fo:t:ei.gn bodies and produce 
some degree of irritation or, as in the case of mineral oils6 
produce a type of lipid pneumonia.. It should be poirited out, 
hoW£)Ver (J t.ha.t the body does possess mechanisms for removing 
insolttbJ.e materials deposited in the alveolar' sacs. The 
question then concerns the efficiency of these mechanisiris .. · 
Small quantities of particles are usually handled without 
inci.dence by various t.ypes of tissue cells·which engulf them 
and prevent harm, but in cases of 1~!'~9'Lq!!_C'I.nt;t ties_()f._pa:r:-____ _ 
t~icles,. the mechanism breaks down and fibrosis of the tissue 
frequently results .. 
If it is determined that a material may be administered 
by inhalation into the lungs, then the next step is to obtain 
,\ arr aerosol o£ the opt:im.um particle size range of bet.ween 0. 5 
:::a:nd 5.0 microns.. n~ is n.ecessary that a large majority of 
-'·the particles fall within ·this size rang~)., r.arger particles 
~1ould deposi-t; on mucosal surfaces and be slowly absorbed, 
while smaller particles would be expelled., The former would 
defeat the purpose of inhalation therapy, whereas the latte1· 
would result in inadequate dosage .. 
In regard to particle size, two other physiolotJ·ical 
factors . should be mentioned., First of all, the :t•espiratory 
sys·tem functions as an efficient humidifying mechanism. It 
is obvious, then, that hygroscopic mat:erials would .tend to 
increase in size when introduced into the lungs. Secondly, 
if a material capable of causing broncho-constriction were 
inhaled,. then the :r.esul ti.ng narro'tved lumen of the aj.rways 
could conce.i vably rednc(~ the amount of drug reaching the 
alveolar· spaces ... 
Fin.ally, it should be pointed out that the rapid 
absorption of materials by the lung depends upo;n the effi-
ciency of the absorption surface6 If the lung is affected 
by some disease process, then absorptive efficiency is 
reduced.. For example, in pneumonias, up to 75 per cen·t of 
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the alveolar spaces could be rendered usele£::s for either 
respiratory or absorpt:i ve function., It is necessary to con-
sider the presence of pathological P¥)~!ft~n?~Y __ ~Q~dit_.ions __ when~-­
aeroso.l inhalation therapy is being considered for anything 
other than its loc:al effec·ts (24) .. 
There are several ways in which a medicinal can be 
formulated 'Vd th a liquefied gas to produce an aerosol.. If 
,;~:he medicinal .is soluble dir~:wtly in t:b.e propellant, a clear 
B'Olution is produ>.o:ed., lvh.en this solution is dispensed from 
the container, th.(;~ propellant vlill va.porize, leaving b£~hi.nd 
a fine d.ispersion o:f the medicinal either as liquid 0.7~q solid 
particles, depending upon its physical characteristics. Proper 
choice of propellant, valve, and actuator will produce the 
proper s.ized particles. However, most medicinals are not 
soluble directly in the propellant and may be rendered soluble 
by use of a co-solvent. Considering the number of solvents 
that are miscible with the propellants and yet are safe to use 
internally, the problem becomes apparent. Very few solvents 
fall into this category. Ethyl alcohol has been used in a 
concentration of about 30 per cent as a co-solvent for some 
medicinal aerosols.. The usual advantages and disadvantages 
of ethyl alcohol are present.. Some oth~~r sol vents that. may 
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be useful but have not: been. fully tested to date are; 
polye·thylene ·glycol 200 to 400, methoxypolyet.hylene glycols .. 
dipropylene glycol, and hexylene glycol.. The toxicity of 
these compounds must be considered not only when they are 
given orally but by inhalation as tv-ell. 
Water is a good solvent for many medicinals but, unfor~ 
tunately~ water is not miscible with the propellants. However, 
it may be possible to formulate aqueous syst<~ms in a three-
phase aerosol using sui table baffles t:o produce desir~<:l,_:ear_. -----
ticle size.. 'l'his type of system l..Yould ovel::-corne many of thc-) 
problems dealing with the toxicity of the co-sol vents and the:1 
For those medicinals which are insoluble, or can be 
made insoluble il:~ the propellant., a dispersed system may be 
possible .. 
To have t:h.o~ lungs retain a rea.sonable percen·tage o.f 
pa:c·ticles inspl,red, the particles must remain above a given 
critical radius, which has been shown to be approximately Oo5 
mi.cron.. When the medicinals are liquids, the very fine mist 
of droplets which is formed disappears quite rapidly because 
of the sma.ll size of the d.:roplets., This results in droplets 
of varying particle size, many of ·them falling below 0 .. 5 
micron.. This rapid evaporation is due to the decreased pres-
sure within the respira.t:o:cy tract, making evaporation more 
rapid.. The particle size c;:an be stabilized by the addition 
of glycerin, urea" sugar, and some salts. These act by 
decreasing the vapor pressure of the medicinal solution, thus 
decreasing their ra.te <>f evaporation (24)., 
,= 
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Iviany medicinal aqerits lend themselves t~o administration 
by inhalation~ In fact, any drug given by intravenous·injec-
tion can,. in mos.t. cases, be reformulated into a su:U:abJ.e 
aerosol~ 
On the basis of the grea·t number of possible advantages 
of oral inhalation therapy and the.inherent disadvantages of 
many current.ly used dosage forms for the admini.strat.ion o:E 
ant..inausean1:s, i.t: would seem app.t>opriate that stud.ies l::>e con~ 
ducted on the development: of an oral inhalation dosagi::; form 
antinauseant. Thus, the objec·tives of this research project 
will be to develop a series of aerosol formulations and to 
determine their feasibility in antina'l.tseant ·therapy" Appli-
.. cable J:.£ .YJ.t££ and .in Y.i.Y~<?. evalua.tion t.estsv including 
\ stabili·ty stur.Hc;·> ~vil1 be perfo:r·med... 'l'est re~>ult:.s w.:i..ll bo 
compared and corzr;;d . .:tb:'.!d v-Ji.·tJ1 t:he objec·tive of devising use·~ 
ful :Eo.rr.:n.1l.a·cions fo:r. further study ;md development. 
EXPERIMENTAL 
Formulation and Prepara·t:ion 
---.,;olu.-....-,.--.-.. - ·-~..;.. • .;;;..;,~;.;;. 
Initially, a review of the literature. ~li.th special 
emphasis on formulation techniques, propellantsv solvent 
systems 9 and medicinals useful in the treatment of nausea 
was required. 
In the present "mrk, it 'i.ras propos~~d t~o use act.ive 
ingredients of proven 't'lorth in cont ... rolli.ng nausea .• 
Scopolamine hydrobromidea, Diphenhydramine hydrochlorid0J:
1
a' 
Dimenhydrinatec, and Cyclizi.ne lactated 't~e.re the a~rents 
chosen.. All of thc.se compounds have been ust=:-:d ·for sevex·al 
'rhese agen·ts also possess the desir.:.~d solubilit:y for th:Ls 
projectt i .. e., water and/or alcohol solubility., Th(~se 
medicinals may also be administered by intravenous injection. 
which indicated the possibility that, they coulcT be :refc,rtm .. t-
lated into suitable aerosols (24)., 
Since the ultimate preparation was intended f<n: i.nteJ:-~ 
nal uselt it v1as vital +.:hat the propellant chosen po~sess a 
a -· Available from Inland Alkaloid Co. II St .. r,.,ou:i.s, Mo .. 
b ·~ Available 
Mich .. 
R as Benadryl from Parke Dav1.s and Co .. , Detroit~ 
c ... Availab1e as DramamineR from G. D .. Searle and co .. , Chicago, 
Ill. 
R d - Available :::-:1.s Ha:t·ez:Lne from Burroughs Well come and Co .. 11 
Ref~e~>..."::"ch Tri.ang.le Park, N .. c .. 
very low tox1cl.tyo Theref:ore, the propellan:t.chosen wns 
octafluo.:cocyc1oh:rrt.ane 11 Freon c-.::naa;. This compound has a 
reported vapor pressure of 25.,4 ps:ig9 a dens:ity of L. 51 at. 
"/0° F .. , and is nonfla.rrmtable.. Freon c~318 propellant i.s ·the 
31 
most chemically inert of t.he uF.reonn propellants arid has• be1?.Jt1 
appxovecl by the F'ood and Drug Adm:i.nis-t..ratiorl for usc 3.3 ·c't food 
the conunon "Freon" propellan1:s, and is" the:r-efo:cE~,y limited in 
its use in nonfood ae:t:Qs_Qls_,._Ii:_is_also_an--t~xt:re:mely:. poor-------
solvent (25)., 
The choice of sol vent system as \>Jell as p:t<,p<·~llant is 
of cJ:i tica.l importance in any aerosol product.. These agents 
profoundly influence the particle size of the aero::wl produc/c 
n.on ... irxit.at:ing, and compatiblE.~ with the othe1: compone:nts of 
if:he sys·tem., Vory few solvent;s fD.ll int(.>. the above categories .. 
Certain solvents have l:•eer1 m~ntioned in the literatt.'l.re (24L, 
Therefore, on the basis of t;he above ment:i.oned criteria, sol-
vent characteristics, and literature review the solvent sys-
tems chosen eonsisted of varying p:ropo:t~tions of water, alcohol 
95%,and propylene glycol .. The latter two ingredients may act 
as co·-solvents., 'l'he solvents C!hosen have a low ·to~icity and, 
there~fore,. overcome many of the problems encountered in aero-
sol formulation. Propylene glycol also has been reported to 
stabilize particle size (24). 
a - .Available from E. I .. du Pont de Nemours and Co.,·. Inc .. , 
Organic Chemicals Dept., "F~ceon" Products Division, 
Chambers Horks - Deepwater, N .. J. 
I 
.3.2 
t.~ tubes·· ·to d•~te:rmine ·:the type of sys·tem re.sul ting from the 
mixture of sol vents and propellant, to determil1.t:: ·the amoun·t 
of. propellarit necessaxy to dispense all of t:he p:r:oduct, and 
to determine the most. effic:h~nt: methods of ha.nd.l:i.ng the· 
valve mechanisms .. 
Finally, fom· ba.sle sol ven·t.-.propellant. systems were 
chosen :Nn: evalua·tion vlith each of the _:t:ou:r."_<:l~tiy_e __ i.ngr_e_di~'-------
. ents-. On t'l .. volumemvolume basis 6 the f'ormulat:ions w-~:c:·e: 
. b 
Formula A 
Water, purifi1=d " ., .. ., ....... " .. ,. • 
Octaflttorocyclobui:ane (Preon C~31B) ., 
Formula Bb 
.. .. • .. .. .. 
Water,. pu.rifi€~d " " ., 
Alcohol U~ S~ P~ ~ Q 
Octafl uorocyclobuta.ne (Frr:H:>n 
l<'or:mula cb 
.. , .. "' .. 
"' 0 .. ,.. .. c-:na> .. 
" 50% 




Water, p'W:'ified ~ .. I) " • o " .. ,. ~ Q .. 33 1/3~~ 
Alcohol U. S. P. • ., e • • • • ~ e * ~ 16 2/3% 
Octafluorocyclobu·tane (Freon G-318) .. • 50% 
Formula Db 
Water, purified e ~ o ~ ••• ~ •• 
Alcohol U~ S~ Po ~ ~ o .. ~ • ~ ~ .. 
Propylene glycol u. S. P., .. ., .. • .. 













All for·mulatin9 of active ingredien1:s and solvent sys-
tems wa.s pc-:!rformed in 50 ml. volumetric flasks.. The 
Scopolamine HBr and Dimenhydrinate po't'lders were weighed on a 
__ ..... .. " .. _ .. ~------
a ... Available from the Fischer and lJorter Co., Oakland, 
Cal:i.f~ 
b ... The letters "A, B, c, n•i hereinafter referred to in the 
tables of this vmrk refer to .the four formulations c;.\oscribed 







Sru:-torius ba,lancea.. The Diph(·mhydrarnine HCl and Cyc:l.izine 
lactat.e were transferred from corrunerc.ial ampttls to the 
volumetric flasks by use of a 50 ml .. syring-e and needle 
.b uru.t .. 'l,he final 50 ml .. formulatj.ons cont.ained, separately, 
SOO,mg., o£ Scopolamine HBr per 50 m..l.,, 500 mg. of Cycl:i.zine 
lactat.e per 50 ml., 250 mg. of Dimenhydrinate per 50 ml~ ~' and 
300 mg .. of Diphenhydramine HCl per 50 ml. 
I ----='!!.'.ta_1~~.2.1ves, _a_!!~~y E~ __ _ 
'l'he containers used i.n this 'tvork 'tvere aerosol cans 
't•lith domed tops and standard one inch curled openin<;:r made of 
c three piece tin plate ~ 
'l'he valves used in the study w·ere pr~~ssure fill metered 
d valves of 50" 100, or 200 mg. • rrhe valves consisted of a 
tin·~plate m<:m.nt.1.nq cap and a high dens.i·ty polyethylene body 
'ltdt.h· a body orific.:e of 0~ 040 inch~ rf'he stem \'Jas E~tainless 
st+;:el t>J.ith a 0 .. 020 inch stem orifice.. 'rh.e pressure fill ori~ 
fice was 2 x 0.020 inche The outlet valve seal was Buna N as 
was the inlet valve seal. The valves v1ere equipped \V'i th a 
stainless steel sp:t'ing, and the dip tube t-1a.s a polypropylene 
capillary \vi th a 0. 045 inch int:f2!1:'nal diameter .. 
a !'" Available from Aloe Scientific Division, A .. S., 1\.l.oe Co.,, 
S·t. r,ouis, l•lo. 
h ·~ Available from Becton, Dickinson and Coe, Rutherford, N ~ ,r., 
c *· 1\vailable from Continental Can Co., 7:-Te'i.v York, N. Y. 
d Hanufa.cturer' s designation of amount of pr.-oduet: released 
per actuation. Available from Emson Resea:ec;h Jnc., 







Both a regular and a mechanical break-up actuator were 
used in this experiment~ These \-rere used in conjunction with 
an inhalator/cap combinationa.. Both the regular and mechanical 
break-up actuators were one piece plastic with 0.018 inch ori~ 
fices, however, the mechanical break-up actuator also contain(;!d 
a mechanical brealc-up insert. 
!:i!.!JJill J~i.<? t~ 
In thfl..!! current workv all samples "t'lere filled by the 
~------~----~~~~---~~~~,---------pressure filling method using the General Kinetics model 
GK-1200-IA Laboratory Uni tb o In pressure fillin.q·., the product 
is placed in the container at normal temperatu:r:e and sealede 
The propellant is then in·t:roduced under pressure tru:·ough the 
valve., The ·danger of air being entrapped in the containeJ:' can 
bl'~ avol1:Je,d by p'llX'9in9 the con"l::ainer by the addition of a small 
In_ Vitro_ T~.ti-~9:. l?r~~ 
Aftex; tformulating the aerosols according to the pre-
vlously :me:r::-tioned procedures, it was necessary to conduct a 
series o:f: J£t yi~:!:S?. tests to evaluate the products. 
This test. was performed using a sui table pressure 
guagec. It is necessary to determine the pressure of formu-
lations .for several reasons: 
a ... Ava.il,ahle fJ.&om Ernscn Research Inc. 1 Bridgeport, Conn .. 
h ... Available ·from General Kinetics, Ince, A.tlanta, Ga,. 
c - Available as u. S~ Guage from Gt~neral Kinetics, Inc .. , 
Atlanta 1 Ga .. 
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.l) ttl ·aid in . asce:.ctaining. the tmiformi ty of 
formulat;i,.>n .t;-1:1. thin a ~J:ronp of prcH1ucl:::sr 
2) to obsE:u:ve the ef:Eect. of different sol vent .syst.ems 
on the pressure~ 
3) t:c help :find faul t.y seals . and leaks, 
4) to dt;:term:tnc: if pressures are 't'li thin gover:nr.aental 
Tl'I.BLE I~ 
Spr.a.y pattern studies wex·e conducted ·to a:i.d in deter ... 
mining possiblf".! formuli;rtion or valve defects .. · This wa.s 
:;bra.l adap't~o.r attC~.ch.mer:rt1 em fil te:c ·paper a.t varying dist:ances 
~om the actuator and measuring the diameter and shape of the 
spray pattern..~. .An unusual spray pattern would be indica·ttve 
Results of' t:he s:pray pattern studies can be seen :i.n 
TABI~E II,. 
3., A.mount of 1-'la.t<:irial. Released Per Actuation -..---..--... --~--.,.. ...... ~ .... -----~·--'"'"~-----~·~----
As was mentioned earlierjl \\dth ro.etering valves thE~ 
volume of the chamber in which the isolated port:ion of the 
product i.s held det:.ermines the quantity of the spray per 
actuation. However, i:ra.de practice has been to take no 
account of tht~ s:pecific gravity of the productR·propellant 
mixture and. to list valves with di.fferent capac:!. ties as being 
.. F 
··4,-
T. ~ ..... ]" ..... 'li' 
INITIAL PRESSURE OF TH".i! PACKI~GED FORMULATIO:tiiSa 
~:i::seh ScoPolamine h'13r CyclizJ.:..n.~.-L_?.-5:!ta"j:~ · DimenhydrinJ~ A B C D A B C D A B C I!> 
I I 
50 :mg 37 31 33 30 33 33 37 3~ 40 35 33 ~:3 
-1 
100 mg 35 30 33 30 39 37 36 38 36 36 33 •'3 
-r 
200 mg 37 33 30 31 39 38 38 38 38 34 34 37 
a -· Pressure is given in psig" 'tvhich is pounds per square inch gua
1
ge. 
b - This refers to the manufacturerts classification of the valve. 
llilffllllj!lll!ll•,.l,, lii:JIIIJIII: 
DiEhenhydramine HCl 
A B c D 
33 32 36 32 
34 32 34 32 




SPRAY PA'r~rERN STUDIES 
Valve a Scooolamine f-i::Br Cycl~:f:..~nQ._J .. f.l_ctate DimenhYdrinate piphenhydramin.e HCl 
Release ~ ... B c D A B c D A B c D A B c D 
50 mg Reg 6 in .. 1.5~ 1 .. 75 1.5 1.75 1.0 2,.5 2 .. 0 2 .. 0 3 .. 0 2 .. 0 2.0 2.0 2.5 2.0 3 .. 0 2.,0 
1.5 1.25 1.5 1 .. 5 1.0 2.,5 1 .. 5 2.,0 3.0 2 .. 0 2 .. 0 2.0 2.,5 2.0 2.0 2 .. 0 
100 mg Reg 6 in. 1 .. 5 2 .. 0 1.5 2 .. 0 1.0 2 .. 0 ? ~ ... ..... Q ...c; 2.,5 2 .. 0 2 .. :; 2.,0 2 .. 0 3.0 2.0 4 .. 0 3o5 
1.5 2.0 1.5 1 .. 25 1 .. 0 1 .. 25 2 .. 0 2 .. 0 2 .. 0 2 E" .:J 2 .. 0 2 .. 0 3 .. 0 2 .. 0 3.,0 3.5 
200 rng Reg 6 in .. 2.0 2.75 2.0 2.0 2.0 1~5 2.,5 2.0 2.,5 2 .. 0 3.0 3.0 3_.0 3.,0 2.,5 3.0 
2.,0 2.25 1.5 2.0 2.0 1.5 2 .. 5 2 .. 0 2.5 2.0 2.0 2 .. 5 3 .. 0 3.0 2 .. 0 3.0 
50 mg Reg .9 in. 2.0 2 .. 25 2.0 2.5 2 .. 0 3 .. 0 2,5 2~5 3 .. 75 2 .. 75 3 .. 0 2.,5 3.,0 3.0 4.0 3 .. 0 
2 .. 0 1.75 2 .. 0 2.25 1 .. 5 2.,75 2 .. 0 2 .. 5 3.,5 2 .. S 2 .. 5 2.5 3 .. 0 2.5 2.5 2.,5 
100 mg Reg 9 in. 1.5 3 .. 0 2 .. 0 2.5 1.5 2 =\ . - 35 5< 3.5 3.,5 3 .. S 2o5 3 .. 0 4 .. 0 3.5 5.0 4.0 
1.5 3 .. 0 2.0 2$25 1 .. 5 2 .. 5 3 .. 0 3.0 3o5 3 .. 0 2.5 3 .. 0 4.0 3 .. 0 4 .. 5 4.0 
200 mg Reg 9 in .. 3o0 3.0 2.,25 3.,0 3o0 2 .. 75 3 .. 5 2 .. 75 3o25 2.,5 4.0 4 .. 0 4 .. 0 5.,0 3.5 5.0 
2 .. 5 2.75 1.5 2 .. 5 2.5 2 .. 5 3 .. 0 2 .. 5 3.0 2.5 3.0 3 .. 0 4 .. 0 4.0 3 .. 0 4.0 
50 mg Reg 12 in& 2.5 2.75 3.0 3.25 2 .. 5 3 .. 5 3.,25 3.,0 4.5 3.~!5 3 .. 5 3.0 4.5 3.5 4 .. 5 4.0 
2.0 2.5 2 .. 75 3 .. 0 2.,0 3.,5 3.,0 2.,75 4~0 3.,0 3 .. 0 3.0 4.0 3.0 3 .. 5 3.0 
100 mg Reg 12 in. 2.0 4.5 3,.0 4,,.0 2.0 3 .. 5 4.,0 4 .. 25 s.o 4 .. 0 3.5 4.0 5.0 4.5 6.0 5 .. 5 
'2.0 4 .. 0 3.0 3 .. 5 1.75 3.5 4 .. 0 4.,0 4 .. 5 3.,S 3.0 3.5 s .. o 4.0 s.s s .. o 
200 mg Reg 12 in. 3 .. 0 3.75 2 .. 5 3.5 4.0 3 .. 5- 4,.0 3.,5 4.0 3G(i 5 .. 0 s.o 5.-.0 6 .. 0 4 .. 5 6 .. 0 
2.5 3.5 2 .. 0 3.,0 3 .. 5 3~25 3Q5 3 .. 0 3.5 3 .. 0 4.0 4.0 s.o s.o 4.0 5.0 
w 
-..! 
TABLE II {continued) 
~:i::sea 
Scopolamine HBr C~clizine Lactate Dimenhydrinate. Diohenp~drsmin~ ~ 
A B c D A B c D A B c D A B c D 
b 2.0 2 r; 2.,5 2 .. 0 2~0 2 .. 0 2 .. :~ 2 .. 0 2 .. 0 2.0 3.0 3.,0 2.0 50 mg l-"J3 6 in. 1.5 2.0 2.0 oV 
1.5c 1.25 2.0 1.75 2.0 2.,0 2 .. 0 2.0 2.0 2.S 2.0 2.0 2 .. 0 3.0 2.5 2 .. 0 
100 mg MB 6 in. 1.5 2.0 1 .. 5 2.0 2 .. 0 2 .. 0 L.5 2.5 2 .. 0 2.0 2.0 2.0 3.0 2.0 2.0 2 .. 0 
1.5 2.0 1.5 2.0 2 .. 0 2 .. 0 1~5 2.5 2.0 2.0 2 .. 0 2 .. 0 2.,0 2.0 2.0 2 .. 0 
200 mg ~lB 6 in. 1.75 2 .. 0 1 .. 75 2.5 1.5 2 .. 0 2,.0 2 .. 0 3.0 2.0 2.0 3.0 3.0 3.0 2.0 3.0 
1.,25 2.0 1 .. 5 2 .. 0 1.5 2 .. 0 2 .. 0 2 .. 0 3 .. 0 2e() 2.0 2.5 3.0 2.0 2 .. 0 2 .. 5 
50 mg N.B 9 in .. 2.0 2.5 2 .. 5 2.5 3.0 3 .. 0 2 .. 75 2.5 2.,75 3.0 3.0 3 .. 0 3.0 4.0 4 .. 0 3.,0 
2 .. 0 2.0 2.5 2.0 2.5 2.5 2 ... 5 2 .. 25 2 .. 5 3.0 2.5 2 .. 5 3.,0 4.0 4.0 2.,5 
100 mg ~-iB 9 in& 2.0 3 .. 0 2 .. 75 2 .. 5 3.0 3 .. 0 2 .. 5 3.5 2 .. 75 3 .. 0 2 .. 5 3.0 4.0 3.5 3.0 3.0 
2.0 2.5 2.0 2 .. 25 2.5 2.5 2 .. 0 3 .. 0 2.,5 2.5i 2.,5 2 .. 5 3.0 3.0 3.,0 2.5 
200 mg }lB 9 in. 2.5 2 .. 75 2.0 3.0 2.5 3 .. 0 3.0 3 .. 0 4.0 3.0 3~5 4 .. 0 5.0 4.0 3 .. 5 4 .. 0 
2.0 2.5 1.75 2.5 2.0 2 .. 5 2, .. 5 2.5 3 .. 5 3.0 3.0 4.0 s .. o 3.0 3.0 3e5 
.50 mg l•lB 12 ino 3 .. 0 3.25 2.0 3 ... 0 4 .. 0 3 .. 25 3.25 3 .. 0 3.25 3o0 3 .. 5 3 .. 5 4o0 s.o SeS 3.5 
2 .. 5 2 .. 75 2.0 2 .. 5 3.0 2.75 3 .. 0 2 .. 5 3 .. 0 3o5 3 .. 0 3 .. 0 3.5 5.0 5 .. 0 3.,0 
100 mg .MB .!2 in ... 3 .. 0 3.,25 2.75 3.75 4.0 4.0 2 .. 75 4.5 3 .. 25 3.,5 3.0 3 ~ . .., s.o 4o5 4 .. 5 4.,0 
2 .. 5 2 .. 75 2.25 3.,0 3 .. 0 3 .. 0 2.5 4 .. 0 3.0 3 .. 0 3.0 3.0 4 .. 0 3 .. 5 4 .. 0 3.,0 
200 mg }J...B 12 in., 3.,0 3.5 3 .. 0 3.,5 4.0 4 .. 0 3 .. 25 3.75 5.0 4 .. 5 4.5 5 .. 0 7.0 s.o 5 .. 0 SoO 
2.0 3 .. 0 2 .. 0 2 .. 75 2.5 3.5 3o0 3 .. 5 4.,0 4.0 4 .. 0 s.o 6.0 4.0 4.,0 4.5 
-· 
a - These figures denote valve release capaci~:y as t>tated by the manufacturer, actuator type 
(Reg=regular, MB=mechanical break-up); and th:s d.:Lstance from the oral adaptor at which the , .... 
measuremen·ts were made .. 0: 
1 !!rF~'!1"FII~ f 1- · "~ -,!11111' ··:-rm-11~;;-:n·liL _____ _ 
b - This is the spray pattern diameter, in inches, resulting from actua·tion without the use of 
the oral adaptor. 
c - This is the spray pattern diameter, in inches, resulting from actua·tion using the oral adaptor& 




abl<.-'l to deliver a certain number of milligrams per 
actuation (3).. 'I'herefore, for each particular formula 3 :t·t 
is necessa:r:·y to determine the amount of product released pex· 
actuation., The uniformity in delivery from metering valves 
is .:indispensable in the development of dependable medicinal 
p:t'eparat:ionso Limits of ± 15 per cent of the calculated dose 
have been suggested (26) o The amount of produc.~t released ~ms 
compared with the amount stated for each valve by taring the. 
conta.iner 1 actuating five times q.nd re~weighing.. Thi:! ·tve:lgh-
.1 
ing was done on a torsion balance". 
After this and other i-J1 ill.££ tests, satisfactoxy 
formulations 'tvere subjected to a st:ability study., 'l'he af)rosol 
h ·f("'>rmulations were stored in a 'l'helco Model 12 C"~.i'Enf· at a tern~ 
fo.r one month .. This is a.pp:r.·ox:i.m<.:d:ely 
thl.s .st.orage, t:ht~~ :Eox·mulations '\:..;oro ac;.rain b7)s·ted for valve 
release to aid in determining if ·there had been any forrnuJ.a-
tion deterioration 01.~ valve malfunction .. 
Results of the valve release study are tabulated in 
TABLE III., 
B .. 
Results of the valve release study af·ter storage are 
summarized in TABI,E IIIa .. 
-----·--m~--·----~ 
a Available from The Torsj,on Balance Co.,, Clifton, N~ J .. 
b -Available from Central Scientific Co .. ~ Chicago, Ill .. 
TABLE :t:.t! 
AivlOu"NT OF FORN.UI....~TION -RELEASED PER ACTUATIONa 
Valve b Scopolamine HBr C~clizine ~ac~-~ pimenh:ydr in.c:~ DiEhenhydramine HCl 
Release A B c D A B c D A B c D A B ,.. D ..... 
50 mg redo 
c 54 50 50 50 46 50 50 48 52 54 56 56 50 54 48 54 
50 mg ¥ill 50 50 50 50 50 54 52 50 54 50 56 50 54 50 54 46 
100 mg reg .. 90 90 90 96 104 80 80 i38 104 104 90 90 88 104 96 94 
100 mg .MB 90 94 90 92 90 80 92 92 106 102 90 100 88 96 88 92 
200 mg reg .. 164 160 160 178 180 155 162 140 178 164 190 158 170 200 168 184 
200 mg HB 160 160 160 158 184 160 160 140 160 160 166 160 160 170 160 180 
a - The results are the averages of five actuations determined by t.aring the container, 
actuating and re-weighingo Amounts are given in mg. 
b - This refers to the manufacturerGs classification of the valve. 
c - "reg" refers to a regular actuator .. 
d - "!fill" refers to a mechanical break-up actuator .. 
1- ·~- I!IJf.lllnfPfT 1~ -. J:!Ql1l!lrrr ·--.~ 1- ~--:--:-~-;-; ~ r. :-:n.- ~-
,e.. 
!-' 
TABLE !I!a · 
AMOUNT OF FORMULATION RELEASED PER ACTUATION AFTER STORAGEa 
Va~ve b 
R.e.J..ease 
c 50 mg reg. 
50 mg 1-rnd 
100 rng reg. 
100 mg HB 
200 mg reg., 

















Dimenhydrin.:~ piphe:nhydra!r'j_n~.~ !ifl 
B C B D 
50 52 48 50 
48 52 50 54 
92 90 96 88 
92 98 106 90 
160 180 160 180 
158 162 160 190 
a - The results are the averages of five actuations determined by t:aring the container, 
actuating a.nd re-weighing.. Amounts are given in mg. 
b - This refers to the manufacturer • s classificcd:;.:tvn of the valve .. 
c - "reg" refers ~co a regular actuator .. 
d - "1-ffi" refers to a mechanical break-up actuator .. 
1lrJPmliRII' 1'P: 1!"!1 1l! :rt~u;~;,_-:-
~ 
N 
4.. .R.~!:j;;i.<~le S:!: z~--~~:in 9:_ t i..2!1. 
l?arti<:::le size studies were conducted using an American 
Optical microscopea with an ocular micrometer calibrated 
against. a si.-:a.ge nlicrometer for direct measurement.. r1'he cali-
bration \vas done according to the method of Trease (27)., 'rhe 
particles were deposited on slides coated with whit~) petrol a-
tum to prevent merging of adjacent particles and to delay 
evaporation., This general method has been mentioned by 
Tollin. (28). l:licroscopic techniques have been classified as 
being runong the most accurai:e of ·the direct me·t:hods. Micro-
scopic measurement of the actual dimensions of particles is 
more accurate t.han indirec.t methods which measure some other 
. 1 . h . 1 d h . . { 2< ' property of partJ.c es -;;-.rh,1c . 1s re ate ·to t eJ.r s1ze .. J J" 
Pm:.·ticl<.~ siz1~ determination is import.ant because the aerosol 
particl·es nru:r~:;t fall :Lnt:o an optimum size range to give the 
desired effE~cts and advantages of or.;;d inhalation t:her<:1.py .. 
This size range is now generally accepted as being bE.~·tween 
0,. 5 and 5 .. 0 microns.. r.arger particles are deposi 1.:ec1 in thf~ 
respiratory tract above t.he alveoli, whih~ most particles 
belor,.r 0. 5 mieron are lost by exhalation.. '11he formel.~ would 
slow absorpt:Lon and, the.Y:(i!fore, defeat the purpose of inhala-
tion therapy r \'lhereas the latter \rlOUJ.d :r.esul t in inadequat.e 
dosage .. 
Ten particles per slide were counted, using five slides 
at each interval of 6 inches, 9 inches, and 12 inches from 
the acJc.uator.. In the present work, both mechanical break·~up 
a - Available from American Optical Co .. , :rnstrument Division, 
Buf:f.alo~ N .. Y., 
44 
and regular actuators with the oral adaptors were tested. 
The t;hreG distances from ·the actuator "t·lere chosen to give a 
more complete picture of the particle s1ze distribution~ The 
cri·teria for formulation selection \·laS the p.roduc·tion of par-
t.icJ.es 'd t:h an average diameter o:f bet wE~ en 0 ~ 5 and :5 ~ 0 microl\:3 
and with no particle greater than 10 microns. 
TJ;li.s test was also repeated, on ·the aerosols that \vere 
subjec·ted t.o the stabili·ty study men·tioned earlier 5 to deter-
rrd.ne if t.herc~ \vas an :lncrt'!ase .in part:iclc~ size.! on aqing,, 
The results of the particle size determinations are 
indicated in TABl.E IV. 
The results of the particle nize determinations after 
Fo:cmulations complying with est:ablished standards vJere 
then subjected to an iJ2. viyg_ tt"lst using guineu. pigs., 
. . c1' } d Since all of i.:he act~ve ~ngre · 1.ents employ;~ were of 
established effectiveness, a formula·tion could be considered 
E.H .. lCCt~ssful if i·t could be establish.ed tha.t 1:he active ingre-
dient passed the pulmonary membrane bc1.rriers o.nd entered the 
blood stream. 
The test was based on the hypothesis that all of the 
ingredients demonstrate significant anticholinergic prope-r-
ties (30, 31, 32, 33)~ Upon administration, with subsequent 
absorption into the blood stream, bronchodilation should 
occur, and a respiratory rate increase should be 
" 
TABLE IV 
INITIAL PARTICLE SIZE 
Valve a Scopolamine h"Br 
Release A B c D 
50 :mg Reg 6 in. 5 .. 54b 2.88 4.94 4 ... 88 
14.20c 7.81 14 .. 20 11.,36 
100 :mg Reg 6 in:o 7.68 3 .. 74 4 .. 63 4 .. 44 
16.33 8.52 14.20 12 .. 07 
200 mg Reg 6 in. 6.62 2.61 7 .. 23 6 .. 01 
14.20 7.81 17.75 2lo30 
50 mg Reg 9 in. 4.88 2.85 4 .. 83 4.,87 
14 .. 20 7. 81 14.,20 11,36 
100 :mg Reg 9 in,. 7 .. 55 2.56 4.08 4 .. 43 
17.75 10.65 14 .. 20 10 .. 65 
200 mg Reg 9 in .. 6~56 2.58 5 .. 91 5.24 
14 .. 20 8 .. 52 12.78 14 .. 20 
50 mg Reg 12 in .. 4 .. 39 2 .. 84 4 .. 36 4,39 
14 .. 20 7 .. 10 10 .. 65 9 .. 94 
.. 
100 mg Reg 12 in9 5 .. 41 2.,50 4.,06 4 .. 42 
14 .. 20 9 .. 94 14 .. 20 7. 81 
200 mg Reg 12 in~ 6o55 2,.51 5 .. 89 5 .. 21 
14.20 7 .. 10 12 .. 78 9 .. 94 
· !iir:~~!11~ II·' 1'P· 1111!1 ~\ ~·- r .. II' I~ I 
0' -· ·~•>TO·--~--vr-· • 
£yclizine Lactate 
A B c D 
10.86 4.88 3.62 6.19 
28.40 14 .. 20 10~65 10 .. 65 
9.73 3 .. 75 9.,83 4.77 
24 .. 85 14.20 21.30 10.65 
10.01 3.59 9.98 4.81 
28 .. 40 8.52 24 .. 18 8.52 
10.45 4.84 3.34 6.17 
21.30 14.20 14.20 10.65 
9.68 2.84 9.71 4.66 
28 .. 40 7.81 21.30 9.23 
9~30 3.54 9.90 4.71 
21.,30 7.81 21.30 7. 81 
10.41 4.,74 2.83 4.17 
21 .. 30 14,.20 10 .. 65 10.65 
9 "")G-:~ .,v; 2 .. 71 9.40 3.96 
17 ~ 7!5 14 .. 20 21.30 8 .. 52 
9 .. 26 3.,52 9~85 4.63 
21~30 10. 6.5 17.75 9.94 
ii -'11"7"' nr,i111·1 ~ ·rrr --,r11n 
~ 
(.; 
TABLE ;rv f ""'".,.,.H·"·?.·ed) i! \ "--·(.,.;;. ...... _~ .. ::...t 
Valve a Dimenh;Ldrin~~~ 
Release A B c D 
50 mg Reg 6 in .. 5 .. 06 3.48 4 .. 05 4V>~M 
14 .. 20 9 .. 94 12 .. 78 9.;:6 
100 mg Reg 6 ino 6.,08 3 .. 93 4.,53 4 .. 83 
14.20 8 .. 52 14., 20 ' 9.,23 
200 mg Reg 6 in. 5.,94 3 .. 07 5 .. 42 4 .. 22 
14.20 5.68 10.,65 9 .. 94 
50 mg Reg 9 in., 4.98 3.20 3 .. 91 4 .. 76 
14 .. 20 7.,81 8~52 14 .. 20 
100 mg Reg 9 in. 4.79 3*86 4 .. 12 4.,79 
13 .. 49 9.23 14.91 13.,49 
200 mg Reg 9 ino 5 .. 82 3 .. 02 4 .. 76 4 .. 10 
10 .. 65 7. 81 10,.65 12,.78 
50 mg Reg 12 in. 4.60 3.14 3 .. 76 4.,12 
14.20 5 .. 68 14 .. 20 9 .. 26 
100 mg Reg 12 in$ 4 .. 64 3 .. 17 3.,86 4.,26 
10 .. 65 7.10 14 .. 20 12"07 
200.mg Reg 12 in. 5.77 2 .. 94 4 .. 10 4 .. 06 
10.65 5.68 9 .. 94 8.52 




5. 3!:~ 2.,61 
14 .. 20 7 .. 81 
4 .. 33: 3~28 
9.,94 8.,52 
7 .. 70 2 .. 69 
14.20 4.97 
5.24: 2.56 
14 .. 20 4.97 
4.22 3.20 
12 .. 07 9.,23 
7 .. 63 2 .. 60 
12.78 4.97 
4 .. 96 2.06 
8.52 7 .. 10 
3 .. 71 3 .. 18 
14.20 7.81 
5.89 2 .. 47 
l7o75 5.68 
c 
3 .. 68 
9.23 
4.56 










9 .. 23 
4 .. 46 
10 .. 65 
3 .. 45 
10 .. 65 
1'-11~ 1- IW' 
D 
3 .. 95 
8 .. 52 
4 .. 17 




7 .. 81 
4 .. 16 
7.10 
3 .. 85 
5e68 
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TABLE IV ( con:tinu.ed) 
Valve Scopolamine h"BJ.~. Cvclizine Lactate a _...... Release A B c D A B c D 
50 mg I>ffi 6 in. 2~61~ 1 .. 74 4 .. 74 4 .. 40 10 .. 31 2 .. 95 3.,"27 4 .. 19 
7.10 7 .. 10 9 .. 23 9~23 28.40 7 .. 81 8 .. 52 8 .. 52 
100 mg 1-S.B 6 in. 6.06 2.63 4 .. 03 4 .. 43 8.17 1.56 9.77 4.76 
12.07 8.52 9,.94 865·2 28.40 4 .. 97 21.30 8.52 
200 mg bi'J3 6 in .. 6.60 2.10 6.92 5.,07 8.,90 3.52 9.,80 4.13 
14 .. 20 7.81 14 .. 20 10 .. 65 24 .. 85 8 .. 52 28.,40 8.52 
50 mg MB 9.in., 2 .. 58 1.68 4.69 4 .. 39 10 .. 27 2 .. 91 3e24 3.79 
7. 81 4 .. 97 10 .. 65 9 .. 94 28 .. 40 7 .. 81 7 .. 10 8.52 
100 mg !lill 9 in .. 5.96 2.51 3.97 4~42 8 .. 14 1 .. 55 9.71 4.64 
14.20 5 .. 68 14 .. 20 10 .. 65 14.20 3.55 28 .. 40 9.94 
200 m.g l-iB 9 in .. 6.55 2.04 5.89 4.,96 8 .. 51 2.93 9,.77 4.03 
17.75 7 .. 81 21.30 10~65 21.,30 10.65 28.40 8.52 
50 mg MB 12 in. 2.-57 1.66 4 .. 23 3 .. 68 8.09 2 .. 27 2.71 3.02 
5.,68 3 .. 55 14 .. 20 7.81 17.7S 5.68 7.81 6~39 
100 mg MB 12 in. 5.34 2.,34 3.92 4 .. 35 8.12: 1.41 9.,39 3.89 
14.20 7.10 14.20 10.,65 17. 75; 3.55 21.30 7.10 
200 .mg MB 12 in. 6.49 2'"03 4 7~ .. ~ 3 .. 98 8.22: 2.22 9.73 3.93 
14.20 4.97 14 .. 20 7 .. 81 28 .. 40 4.97 21~30 8.52 
~ .... 
""~ •,c .• , .. ,...._...-.,,. '"""""~-r··-- '" -·~""''" 
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TABLE IV (continued) 
Valve a Dimenh:r:drinate DiEhenhxdramine HCl Release A B c D A B c D 
50 mg l•tn 6 in .. 4 .. 36 3 .. 29 3.89 4. .. 97 $~27 2.,;53 3.34 3 .. 54 14.20 8.52 7 .. 81 j~-~1~ 20 9:.023 7. 81 12 .. 07 8 .. 52 
100 mg !-'1B 6 in .. 3.66 3.28 4.44 4 .. 81 3.59 3.24 3 .. 71 3 .. 27 
9.52 7.10 9 .. 94 14.20 11.36 8.52 9 .. 23 8 .. 52 
200 :mg MB 6 in .. 4.42 3.02 4.54 4.10 7.58 2.59 3.79 3.21 
9.23 8 .. 52 8.52 12.78 14.20 7.81 12.07 4.,97 
50 mg HB 9 in. 4.19 3.18 3 .. 88 4.76 5 .. 21 2 .. 27 3.32 3 .. 44 
10.65 7. 81 14 .. 20 12.78 17.75 6.39 11.36 7.81 
100 mg I•lB 9 in. 3.65 3.,01 3.28 4 .. 77 3.56 3.15 3 .. 68 3.21 
8.52 7 .. 81 13 .. 49 14 .. 20 12 .. 78 8.,52 9.94 7.10 
200 mg Y.tB 9 in .. 4.29 3 .. 01 4.43 4 .. 09 7 .. 54 2.50 3.71 2.85 
10~65 5.68 12 .. 78 14 .. 20 14 .. 91 4.97 9.23 5.68 
50 mg HB 12 in. 2 .. 61 3.17 3 .. 58 4 .. 03 4.83 2 .. 04 3.31 3 .. 18 6.,39 5.68 10 .. 65 14.20 12.78 4 .. 97 11.36 4.97 
100 rng lffi 12 in. 3.,54 2.90 3 .. 15 4 .. 25 3.,24 3 .. 10 3 .. 66 3.17 9,94 4 .. 97 6 .. 39 13.49 9,.94 7 .. 10 10.65 5 .. 68 
200 mg MB 12 in. 3.86 2 .. 93 3.98 4.,05 5.10 2 .. 46 3.31 2.74 7 .. 10 4.97 9 .. 94 9.23 12~78 4,.97 6 .. 39 4 .. 97 
a - These figl:u.-es deno·te valve release capacity as stated. by the mc:mufacturer, actua-tor 
type (Reg=r·eg"ular, MB=mechanical break-up} g and i.:he distance ft·om the actuator at 
T,..rhich the particles 'tvere collected .. 
- -llllr.'lJTIIr:JI 11111111 
~ 
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b - The figure in this position is the average diarne~cer of 10 par1i:ic1es counted per slide 
using 5 slides for a total of 50 particles., Data is in microns., 




P~~~TICLE SIZE AFTER STO~~GE 
Valve Scopolamine HBr Cyclizine ~~ctate Dirnenhvdrina t..:e Dipher~ydramine HCl a -Release B D B D B c B D 
50 ng· 6 in .. 3 17b 4.26 4 .. 37 4.06 3.68 4.0S 3.32 4.02 .. c 
7 .. 10 7.10 8.52 9 .. 94 8.52 7.10 8.52 7.81 
100 rng 6 in .. 3.64 4.00 3 ... 35 4 .. 03 4.30 4.27 3.83 4.50 
4.97 7.10 8.52 7 .. 81 7.81 8 .. 52 9.94 9.,94 
200 mg 6 in., 3 .. 83 4.35 4.52 3 .. 46 4 .. 10 4 .. 17 4 .. 06 4 .. 36 
7.10 7.10 8 .. 52 9 .. 23 9 .. 94 6.39 9.94 9.23 
50 mg 9 in. 2 .. 83 3.55 3.72 3.15 3.33 3.46 3.28 3.82 
7 .. 81 6 .. 39 8 .. 52 9 .. 23 7.81 7.10 9.,23 7.10 
100 mg 9 in. 3 .. 38 3.65 3.,24 3 .. 59 4 .. 23 3.61 3.32 4.44 
7.10 6 .. 39 5.68 7.10 7.10 5.6€1 4.97 7 .. 10 
200 mg 9 in. 2.98 3.86 3 .. 56 3.10 3~56 3 .. 88 3 .. 81 4.27 
7.10 4.97 5 .. 68 4 .. 97 7 .. 81 7.10 7 .. 81 8.52 
50 mg 12 in. 2.81 3 .. 08 3.15 3 .. 10 2 .. 91 2.,87 2.46 2.67 
5.68 5 .. 68 5.,68 6,.39 4 .. 97 7 .. 10 6.39 8.52 
100 mg 12 in. 2.49 2.60 2.32 2 .. 71 2 .. 75 2 .. 64- 3.08 3.31 
7 .. 10 4.26 5 .. 68 4,97 7 .. 10 7 .. 10 9 .. 23 7.10 
200 m9 12 in. 2 .. 93 3.27 3 .. 08 2.77 2 .. 83 3o18 3.29 3.07 
7,10 4.97 7.10 7"10 4,97 6.39 9.94 4 .. 97 
a - These figures denote valve release capacity as stated by the manufacturer and the 
distance from the actuator at '1¥hich ·the particles ¥Jere collected.. ?:Iech.anical 
break-up actuators were used in this tes·t.. 
!1~~11flrr1 11-.- llf"!!l:! 1 ~~ --r- 1:1 - -~ml~lJ:I;I·.-: I : Tl.-.-~---- ~-- T I :· Ti ~~ -·· r• rr' ;-- -rr, ,-,.,mrTr·r-- "' , 
~ 
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b - The figure in this position is the average diameter of 10 particles coun·ted per slide 
using 5 slides for a total of 50 particless Data is expressed in microns~ 
c - This is the largest single particle of the 50 par-'cicles observed .. 
in micronse 
mr:mi~Tl. -~~r.r!ll!l·a --, "]..[II, ~:rrr.-~1:11 .~.:- 1· r ... 
Data is exp~essed 
(.:; 
?--; 
ob;::;orved (34{, 35)~ Througll'the use of placebo formulat..ionf~f 
which consis·ted of all substance[3 with t:he excep·tion of the 
acti vc ingredients, in conjunction w:l th th(~ formuJ.at:ions con·· 
1:ain:i.ng the active ingredients, t:he normal "excitatory 11 
increase in respira·tion could be observed and compensated for 
in the results o It should be noted that it Has not: necessary 
·to tranquilize or sedat(') the experimental animals prior t.o 
testing, therefore, there should have been no interference 
from othtn" drugs.. The medication was administered to t:he 
test animals by inserting the oral adaptor directly into the 
mouth and actuating ·the e:1erosol. Animals given placebos were 
not re-tested for at least one hour after administration, and 
animals given a formulation containing an active ingredient 
24 hours~ 'rhc.so Lime inte:eva1s should be sufficient to clind*· 
nate the c1a.nger of an overlap o:F. re:,;u.lt:s from one ·test to 
anoU1er.. A period. of ·three minu:tes v1as chosen as the time 
limit for an ac~rosol for-mulation to exert an effec·t. The 
normal respiratory rate was observed, as well as that. three 
minutes after placebo administration. Then, the rate three 
minui:es after active ingredient administration \•las determined .. 
Since ·the purpose of the in: .YJ .. Y~~ t.est -v1as t:o demonstratE.~ that 
the medication entered ·the blood stream of the ·test animal, 
•the change in respiratory rat.e should provide ample .evidence 
of this facta 








1 B - D 
TABLE V 
!li ~ RESPIR~TORY RATE STUDIES 
Cyclizine Lactate Dimenh~idrJ..~ Diphenhydramine H~l 
B D B I c B D 
b Normal Rate 78/80/78 80/80/82 84/78/80 98/96/96 90/90/90 80/78/82 100/106/110 98/98/lOt 
Increase 
Over Normal 
V.1i th Placebo c 









6/6/2 8/16/22 4/2/4 2/6/4 34/32/24 12/16/20 24/28/20 10/12/24 
.... d" . e .Lngre ~e111: 
a - In addition to respiratory changes, the sedative effect of Scopolamine HBr was visually observed. 
b - This indicates three observations of the normal respiratory rate per minute, determined at one 
minute intervals. 
c - Tl!is indicates three cbservationst conducted at one minute intervals,. of the increase in 
respiratory rate over normalu three minu·t.es after placebo administrat:.ion. The increase is 
attributed to "excitement." 
d - This indicates three observ·ationse conducted at one minute inbervals, of the increase in 
respirat.ory rate over norFtal~ three minutes after active ingredient administ"tation. 
e - This is t.he increase in resp.iratory rc:.te per :minute that is attr:Lbute~d to the ?,ctive ingredient .. 




All of the formulations used 'tvere three pha~3e aerosol 
systems... ~rhis was to be anticipated due to the extremely poor 
solubility characteristics of the propellant, octafluorocyclo-
butane, and the use of polar solvent systems.. The solven:t 
systems trez·e seen to be quite sa.tisfaci.:ox·y for solubilizi:.n9 
the active ingredients.. In addition to thei.r solubiliz:i.n9 
properti,esr. the various co-solvents used \..rere chosen for the 
possible influence they would exert on particle size. 
Consistent aerosol pressur:e was observed within :f.o:rmt:t"~ 
lat.:I.on g,r;'O"J.ps.. J.\t') indica-tt~d :l.n t.he literatu:~:·e (24) r p:cepa.ra,= 
tions co:nt<:.l.inin.g propyl<~ne g-lycol g~:::nerally demonstrated a 
sor::K:l\vha.~;: l·ower pressure. Only one -faulty seal was not.:od 1.n 
any of t:he pressurized pacl~agE:·s! and t.his appea:x.·e:?.d to be dut1 
to fauH::y crimping. No fo:nnu.lation had a pressu.-ce in excess 
of 40 psi-g., i;he.refo.r$t any of these aerosols could bt':! packaq~"ld 
m:t·t only i.n i:.in~·pl ate sb;:el, but also stainless steel and 
sui ta:t>le coa-t:ed gla.ss containers ( 18) .. 
'l];~he sta.bili ty study yielded no Ewidence of container 
or fornn.nl.a degrada:tion, but, as \•Tas mentioned previously, tin-
plate cont.aiJ.1€\rs are at t.J.mes susceptible to attack., Glass 
and st:a:li.n.less s·teel containers are, of courseli practically 
corrosio:n free ... 
Spray pat:tern st.udies were conducted to a:id in. deter-
m:i.rdnq possible fo:rmulat.ion or valve dc~fec·ts. All pati::.erns 
observed weJ.4 e circular and increased , in diameter as the 
distance from the actuator was increased. Also, the patterns 
formed lvhile using an oral adaptor were smaller than those 
foxmed without the use of an oral adaptor. All formulas 
appea:r:ed to be uniform and consistent in this test .. 
The amount of formulation released per actuation was 
consistent w·i thin a product groupr falling within the gen-
erally acceptable + 1.5 per cent (26)., This reproducibility 
is ext:t·ernely important in medicinal aerosols~ AJ.so, no 
r.d.fj.cant changes ~-;rere noticed in amounts released after aging., 
This would seem to indicate that there was no :formula:tion 
alteration ox· valve malfunct:i.on on storagt.:~. Generally, it 
can be said that the 50 mg., valves dispensed 50 mg .. of mate-
sli\Jht:ly 1t~ss t:J:u;n'l. 100 mg.,, and the 200 mg,, valves usually 
1\.s mentioned previously, particle size is Qf cr:i.tieal 
imt>crtance in any a~'::r.osoL. rrhis is undoubtedly Ol'lfJ of the 
most important in ~.2. t,;.::~sts that was conducted. The c:t:·i··· 
teria for formulation selection \vas the production of par~· 
ticles with an ave:1:·age diarnetex: of between 0. 5 and 5. 0 
mic1:-on:3 and with no particle greater than 10 microns .. 
P.a.rt:i.cle sizes lvere reduced considerably through th<:: use 
of the mechanical broak-up actua·t.or. This type of actuator 
is generally reccmurtc:md(::!d fo:t.· any wa·ter based aerosol (24). 
Formulations "A", contaj.ning equal parts of water and 
octaflum.·ocyclobuta;ne, and 11 C", con.taining water, alcohol 6 
and octafluorocyclobutane in a ratio of 2:1:3, did not pass 
the established requirements, \vith t:he exception o:f formula 
56 
11 C" containing Dimenhydrinate. as ·the acti v.e i.ngredient. ThiB 
variation may be due to the influence of the active ingred:i.(~nt. 
since all other components within the group are constant. 
Formulas "B", containing water, alcohol, and octafluorocyclo-
butane in a 1:1:2 ratio, and 11 D", containing water, alcohol, 
propylene glycol and octafluorocyclobutane in a 1~1:1~3 ratio, 
were shown to pass the requirements, again with the exception 
of "D" con·taining Dimenhydrinate as the active ingredient: • 
. The "p:comhdngu formulations that were tested f.ollot·d.ng the 
s·tabili ty study also yielded satisfact:ory resul tso Therefore, 
it. t-.ras concluded that there was no increase in particle siz<) 
on a£{.:i.:ng .. 
Form1Jlations complying with es·tablished in vitro _,_,_ -r--
standards 1v-ere subjected t.o an !D. y,:,hYQ test using guinea pJ.g·,s ... 
As can be seen f:r·om the increase in respb:u·tory .r.ate :follo'W-
ing active ingrectient administra·tion, it appears that: the 
m~dicinals did~" in fact, en·t:er the blood stream and provoke 
a response. 'l~herefore, the formulas considered valuable,· on 
the basis of this study, are: 
I 
lvater, purified .. • • 0 • • e • • • 
Alcohol u. s. P. ~ ~ ••••••• 







contaird.n.g Dimenhydrinate as the acJcive ingredient .. 
II 
lvater, purified ..... e " • $ ...... 
Alcohol u. s. P. ~ ~ • ~ • $ • ~ ~ 






containing Scopolamine HBr, Cyclizine lactate, Dimenhydrinate, 
or Diphenhydramine HCl as the act.i ve ingrediente 
I :f. I 
Water, purified ... a .. ~ ., .. ~ ., • ., • 16 2/3% 
Alcohol Uo So P. • ~ ~ • s •••• e • 16 2/3% 
Propylene Glycol U. S .. P., e ... ., .. ., • 16 2/3% 
Octafluorocyclobutane (Freon C-318) .. • 50% 
5'1 
containing Scopolamine HBr, Cyclizine lactate, or Diphenhydramine 
HCl as ~:he active ingredient .. 
SUM11ARY 
1. The liter.atux·e surveying the history of aerosols, 
the aerosol principle, var:ious aerosol systems,. prope11an·ts, 
containers, valves, packaging methods, applications, and oral 
inhalation therapy has been p.t·esented .. 
2. The :Eac·tor.s influenci11g tl1e choice of ingJ:I)edic~nts 
and procedures.used to develop preliminary formulations have 
been discussed., 
3. Applicable in v~ evaluation studies were pre~­
sented ... The studies tested for initial pressure of the 
packay;ed f;~ir:mula .. tions: spray patt,er.n.v amount of material 
released per a.ctUiYI.:ion, <J.nd part::lcl·tl size., 
4~ A .sb:t..b:tli ty si.:udy was pe:t'forme~d on promising 
formulat.ions,. Aerosols were re-checl<ed for amount of formula 
:r:eleased per actuatj,on and particle size., 
5" Formulations complying \vi th .ill vi t,;£.2. standards were 
then stlbj.ect:ed t,o an :in ,Y.,iY2, evaluation to de't:ermine whether 
the active ingredients t:~nterf~d the blood streams of the 
exper:i.meni:.al animals .. 
CONCLUSIONS 
A study has been conducted to determine the possibility 
of developing an oral inhalation dosage form ant:i.nauseant .. 
The results -of this study indicated that the develop-
ment of an aerosol useful in the tx·eatment of nausea is 
possible,.. Consiste:r1t, reproducible valve release, spray 
patter·n., and particle size results 't-lere demonstrated before 
and after aging studies.. Since all of the active ingredients 
employed \-Jere of proven effectiveness, a formulation would 
appear .successful if i·t could. b~:.1 established that the active 
ingredient passed the pulmonary membrane barriers and entered 
the blood streamc Results ob·tained f:tom the animal studies 
indicated ·that the active in~rredients did en1:er the blood 
stream ·to presumably exert their characteristic action .. 
As discussed previously, an antinauseo.nt effective via 
oral in.'h'alation 1-lOUld offer many advantages oveJ: conventional 
antinauseant dosage forms.. 'rhose screened formulations com-· 
plying ·~dth established. criteria appear to have specific 
therapeu-tic possibilities. 
Aerosol formulations of the type studied in this experi-
ment may find application vli th a \vide range of active ingredi-
ents.. Other druqs that may prove more effective when applied 
as aeroso.ls than "t•:hen administered by other means may include 
antihistamines, anti-infective a<Jen·ts, analgesics, sterols, 
steroids, ant.itussive agents, hormones 1 cardiotonics. 
60 
further st1.1dy before t:h.ey could be used ar3 1 :i.cp.t.i.f.it::d qas aero~· 
sols~ H.ot-;'ever ,. once their behavior in t:hc 1iqu.i£ied qases is 
determined ( solu.'bili·ty, stability, toxicity, etc. ) thi~~y would 
bt:; readily accepi.:able as aero.:;ols ( ;:4) ~ We must keep in mind., 
however, ·that the problems of aerosol fonm.tla-t:Lon mus·t be 
studied in vimv of each other~ and that: in resolving one 
proplem \·;e may create another~ Aerosols desirjnc~d for inhal a·-
tion t.herapy must be carefully balanced systems capable of 
delivering- the amount of drug- to that portion of the respira-
·tory system in Hhich it: 'tvill bt~~ mos·t effective. 
The resul t.s of this study provide encourag·ernent for 
fu·ture work in this areaG Based on the findings of this 
offo:r:f.{ pot.ent:ial aciva.n'l:ages for a wide range of :i.ngredJ.cnt.s 
industry~ The use of 
previously unreported cornbina.tions of acti v<~ ingrE-~dients, 
solvent syst.ems.., and propellants present 6 as they did in this 
project 1 interestinq and stimu..lat.ing possibilities for new 
or:i.qino.l research and developmen·t. 
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